As a National Cancer Institute-designated comprehensive cancer center, City of Hope’s pancreatic cancer program is uniquely positioned to provide personalized and comprehensive treatment plans, along with access to groundbreaking clinical trials. City of Hope has been named one of America’s top cancer hospitals by U.S. News & World Report for over a decade and has one of the most experienced pancreatic cancer programs in the country. Our world-class experts offer pancreatic cancer patients, including those with complicated cases, access to a wide variety of trials, evaluating leading-edge treatments and innovative therapies.
KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
NCT04853017: Principal Investigator
Vincent Chung, M.D.,
is actively recruiting patients for a Phase 1/2 study on the benefits of ELI-002 Immunotherapy as adjuvant treatment for patients with Kirsten rat sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma and other solid tumors.
Patient Enrollment Qualifications
KRAS/NRAS mutated (G12D or G12R) solid tumor
Positive circulating tumor DNA despite prior standard therapy, including surgery and chemotherapy/radiation where applicable
Screening computed tomography (CT) is negative for recurrent disease
Metastatic Pancreatic Cancer With Inherited BRCA Mutations
NCT04548752: In this randomized Phase 2 clinical trial,
Vincent Chung, M.D.,
studies the potential benefits of adding Immunotherapy to olaparib alone as maintenance therapy for patients facing metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations.
Must have a germline BRCA 1 or BRCA 2 mutation from a CLIA-approved lab
A diagnosis of metastatic pancreatic cancer receiving platinum-based first line treatment
At least four months, with no more than six months, of first line treatment
NCT04887805: Principal investigator
Vincent Chung, M.D.,
will be recruiting patients for a Phase 2 study on the benefits of lenvatinib and pembrolizumab as maintenance therapy in treating patients with advanced unresectable pancreatic cancer.
A confirmed diagnosis of unresectable or metastatic pancreatic cancer having received first or second line treatment
At least four months of first line treatment with tumors showing positive response to chemotherapy
NCT04172532: Principal investigator
Vincent Chung, M.D.,
is actively recruiting patients for a Phase 1/2 study on the potential benefits of M3814 (Peposertib) when given in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma.
Patient Enrollment Qualifications
A pathologically confirmed diagnosis of pancreatic adenocarcinoma
Have already received four to six months of first line treatment with tumors showing a response to chemotherapy
